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Background
AIDS-related lymphomas (ARLs), which include Burkitt
lymphoma and diffuse large B cell lymphoma (DLBCL),
are a heterogeneous group of lymphoproliferative disor-
ders that occur in the setting of HIV-mediated immune
suppression. A subset of cases are associated with Epstein-
Barr virus (EBV) infection. EBV expresses latent viral
oncoproteins that constitutively activate the transcription
factor NF-B, a potent inducer of genes involved in pro-
moting B cell survival and proliferation [1].
In immunocompetent individuals, lymphomas that are
not associated with EBV can also display increased NF-
B activity, and recent reports have described mutations
in regulators of NF-B. One of the frequently mutated
regulatory genes is TNFAIP3, which encodes A20, a ubi-
quitin modifying enzyme involved in the termination of
NF-B signaling. Mutations resulting in the inactivation
of A20 have been found in a significant proportion of
marginal zone lymphomas [2], classical Hodgkin’sl y m -
phomas and primary mediastinal B cell lymphomas [3],
a n dD L B C L s[ 4 ] .I nA R Lt h er o l eo fN F - B activation
and the incidence of mutations in A20 have not been
described.
Materials and methods
We evaluated archival formalin-fixed paraffin-embedded
tissue samples of AIDS-related lymphoma for genetic
alterations in A20. Tissue was collected through an
international collaboration between Weill Cornell Medi-
cal College in New York, NY, and Siena University in
Siena, Italy. A tissue microarray with 48 cases of ARL
was prepared, and characterization of viral status and
lymphoma subtype were determined by immunohisto-
chemistry and in situ hybridization for Epstein-Barr
encoded RNA (EBER). Fluorescent in situ hybridization
(FISH) was used to evaluate for genomic deletions in
A 2 0 ,a n dt r a n s l o c a t i o n so fc M Y C ,B C L - 2 ,a n dB C L - 6 .
Direct sequencing of the coding region of A20 was per-
formed to evaluate for additional mutations.
Results
F I S Hw a sp e r f o r m e do n4 8c a s e so fA R L .O f2 1c a s e s
with successful hybridization loss of heterozygosity at
the A20 locus was observed in 6 cases (28%). Cases with
A20 deletion included three diffuse large B cell lympho-
mas, two Burkitt lymphomas, and one Burkitt-like lym-
phoma. Two cases were positive for EBER but all were
negative for latent membrane protein-1 (LMP-1). Partial
sequencing of approximately 70% of the A20 coding
regions in 23 cases did not reveal additional mutations.
Conclusions
A20 may represent a tumor suppressor gene in a subset
of AIDS-related lymphomas. Inactivation of A20 may be
an alternative mechanism of NF-B upregulation in the
absence of LMP-1.
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